Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

8.48
-0.1300-1.51%
Volume:16.68M
Turnover:142.42M
Market Cap:8.35B
PE:-20.42
High:8.81
Open:8.63
Low:8.32
Close:8.61
52wk High:8.95
52wk Low:1.83
Shares:984.97M
Float Shares:194.00M
Volume Ratio:1.36
T/O Rate:8.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4153
EPS(LYR):-0.6189
ROE:78.05%
ROA:-36.89%
PB:-15.93
PE(LYR):-13.70

Loading ...

ImmunityBio Partners With Biopharma and Cigalah to Launch ANKTIVA in Saudi Arabia

Reuters
·
Yesterday

Immunitybio Partners With Biopharma and Cigalah Healthcare to Launch Anktiva® in Saudi Arabia for Bladder and Lung Cancer Patients

THOMSON REUTERS
·
Yesterday

Immunitybio Inc - Anktiva Available for Distribution Within 60 Days

THOMSON REUTERS
·
Yesterday

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

Benzinga_recent_news
·
Yesterday

ImmunityBio partners with Accord Healthcare to provide Anktiva access

TIPRANKS
·
Feb 19

Immunitybio Expands Access to Anktiva® in EU With New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

THOMSON REUTERS
·
Feb 19

ImmunityBio signs EU ANKTIVA distribution partnership with Accord Healthcare

Reuters
·
Feb 19

ImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug

Dow Jones
·
Feb 19

Analysts Have Conflicting Sentiments on These Healthcare Companies: ImmunityBio (IBRX) and Bausch + Lomb Corporation (BLCO)

TIPRANKS
·
Feb 19

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Feb 18

ImmunityBio rises 18.3%

TIPRANKS
·
Feb 18

ImmunityBio gets Anktiva marketing authorization by European Commission

TIPRANKS
·
Feb 18

European Commission grants conditional marketing authorization for ImmunityBio ANKTIVA with BCG in NMIBC CIS

Reuters
·
Feb 18

Immunitybio Receives Authorization From the European Commission for Anktiva® With Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

THOMSON REUTERS
·
Feb 18

ImmunityBio Announces Updated Phase 2 Results for Glioblastoma Immunotherapy Trial

Reuters
·
Feb 18

Why Is ImmunityBio Stock Gaining Tuesday?

Benzinga_recent_news
·
Feb 17

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 17

S&P 500 Futures Fall In Premarket Trading; Masimo, Enlight Renewable Energy Lead

Dow Jones
·
Feb 17

ImmunityBio holds ‘productive regulatory discussions’ with SFDA in Riyadh

TIPRANKS
·
Feb 17

ImmunityBio Establishes Saudi Subsidiary to Drive MENA Expansion

Reuters
·
Feb 17